The abstract is read at the publisher; the summary is JClub's.
Screening 308 mutation-negative familial hypercholesterolemia patients found no LDLR promoter hypermethylation at TaqI sites within a 332 bp region, with an upper prevalence bound of 1.19%.
- Why it matters: Many clinically diagnosed FH cases lack identifiable pathogenic variants, and prior methylation profiling suggested a possible LDLR promoter epimutation that needed recurrence testing.
- What they did: Using Combined Bisulfite Restriction Analysis (COBRA) on peripheral blood genomic DNA, the study assessed methylation across TaqI sites in a 332 bp LDLR promoter segment in 308 mutation-negative patients.
- The result: No epimutation events were detected, implying this specific constitutional methylation is rare and likely does not explain the FH diagnostic gap in this cohort.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.